Charles (Chuck) Maack, Prostate Cancer Advocate/Mentor from the Wichita Kansas Chapter of Us TOO sent me this follow-up to yesterday’s post on Alpharadin.
Interesting is this drug completed Phase II trials in Norway back in October
2007 involving 64 HRPC patients with more than twice as many patients
receiving Alpharadin alive (10 of 33) two years following start of treatment
compared to those that receive placebo (4 of 31). Not perfect, but certainly
Thank you Chuck, as always, you are a compassionate fountain of knowledge to us all.